Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: Similarities and differences

Current Topics in Medicinal Chemistry

Volumn 4, Issue 4, 2004, Pages 473-481

  Stregiou, George S ^a   Skeva, Irini I ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRILAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; HORMONE RECEPTOR STIMULATING AGENT; INDAPAMIDE; IRBESARTAN; LOSARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; OLMESARTAN; PERINDOPRIL; PLACEBO; SARALASIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DRUG CLASSIFICATION; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART PROTECTION; HORMONE ACTION; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; NONHUMAN; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; HUMANS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 3042801841     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451320     Document Type: Review

References (75)

1. Burnier, M.; Brunner, H. R. Angiotensin II receptor antagonists. Lancet 2000, 355, 637-645.
2. Kaplan, N. M. Primary hypertension: pathogenesis. In: Clinical Hypertension. Lippincott Williams & Willkins, Philadelphia, 8th edition, 2002; 80-84.
3. Djau, V.J.; Sasamura, H.; Hein, L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens. 1993, 11 (suppl. 3), S13-S18.
4. McInnes, G. T. Pocket reference to angiotensin II antagonists. London: Science Press Ltd; 1997.
5. De Gasparo, M.; Husain, A.; Alexander, W.; Catt, K. J.; Chiu, A. T.; Drew, M.; Goodfriend, T.; Harding, J. W.; Inagami, T.; Timmermans P. Proposed update of angiotensin receptor nomenclature. Hypertension 1995, 25, 924-927.
6. Birkenhager, W. H.; de Leeuw, P. W. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J. Hypertens. 1999, 17, 873-881.
7. Goodfriend, T. L.; Elliott, M. E.; Catt, K. J. Angiotensin receptors and their antagonists. N. Eng. J. Med. 1996, 334, 1649-1654.
8. McInnes, G. T.; Stergiou, G. S. Clinical pharmacology of angiotensin converting enzyme inhibitors. In: Cleland JGF, ed: Clinicians guide to angiotensin converting enzyme inhibition. London, Churchill Livingstone, 1993, 23-36.
9. Alderman, M. H.; Madhavan, S.; Ooi, W. L.; Cohen, H.; Sealey, J. E.; Laragh, J. H. Association of the renin sodium profile with the risk for myocardial infarction in patients with hypertension. N. Engl. J. Med. 1991, 324, 1098-1104.
10. Alderman, M. H.; Ooi, W. L.; Cohen, H.; Madhavan, S.; Sealey, J. E.; Laragh, J. H. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens. 1997, 10, 1-8.
11. Linz, W.; Wiemer, G.; Gohlke, P.; Unger, T.; Scholkens, B. A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 1995, 47, 25-49.
12. Djau, V. J.; Mukoyama, M.; Pratt, R. E.; Molecular biology of angiotensin receptors: target for drug research? J. Hypertens. 1994, 12 (suppl. 2), S1-S5.
13. Benter, I. F.; Ferrario, C. M.; Morris, M.; Diz, D.I. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am. J. Physiol. 1995, 269, H313-H319.
14. Mooser, V.; Nussberger, J.; Juillerat, L.; Burnier, M.; Waeber, B.; Bidiville, J.; Pauly, N. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 1990, 15, 276-282.
15. Abdelrahman, A.M.; Burrell, L. M ; Johnston, C. I. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J. Hypertens. 1993, 11 (suppl. 3), S23-S26.
16. Burnier, M; Waeber, B; Brunner, H. The advantages of angiotensin II antagonism. J. Hypertens. 1994, 12 (suppl. 2), S7-S15.
17. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. 1991, 325, 293-302.
18. Ichiki, T.; Labosky, P. A.; Shiota, C.; Okuyama, S.; Imagawa, Y.; Fogo, A.; Niimura, F.; Ichikawa, I.; Hogan, B. L.; Inagami, T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377, 748-750.
19. 1 receptor antagonist in hypertensive rats. Hypertension 1999, 34, 1112-1116.
20. Hansson, L.; Lindholm, L. H.; Niskanen, L.; Lanke, J.; Hedner, T.; Niklason, A.; Luomanmaki, K.; Dahlof, B.; de Faire, U.; Morlin, C.; Karlberg, B. E.; Wester, P. O.; Bjorck, J. E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353 (9153), 611-616.
21. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br. Med. J. 1998, 317, 713-720.
22. Hansson, L.; Lindholm, L. H.; Ekbom, T. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity, the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354, 1751-1756.
23. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987, 316, 1429-1435.
24. Massie, B. M. 15 years of heart-failure trials: what have we learned? Lancet 1998, 352 (suppl. I): SI29-33.
25. Hall, A. S.; Winter, C.; Bogle, S. M.; Mackintosh, A. F.; Murray, G. D.; Ball, S. G. The Acute Infarction Ramipril Efficacy (AIRE) Study: rational, design, organization and outcome definitions. J. Cardiovasc. Pharmacol. 1991, 18 (suppl. 2); S105-S109.
26. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. 1992, 327, 671-677.
27. Ambrosioni, E.; Borghi, C.; Magnani, B. Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N. Engl. J. Med. 1995, 332, 80-85.
28. The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000, 342, 145-153.
29. Gansevoort, R. T.; Slutter, W. J.; Hemmelder, M. H.; De Zeeuw, D.; De Jong, P. E. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol. Dial. Transplant. 1995, 10, 1963-1974.
30. Lewis, E. J.; Hunsicker, L. G.; Bain, R. P.; Rohde, R. D.; for the Collaborative Study Group: the effect of the angiotensin converting enzyme on diabetic nephropathy. N. Engl. J. Med. 1993, 329, 1456-1462.
31. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355, 253-259.
32. Ravid, M.; Brosh, D.; Levi, Z.; Bar-Dayan, Y.; Ravid, D.; Rachmani, R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 1998, 128, 982-988.
33. The GISEN Group (Grouppo Italiano di Studi Epidemiologici in Neprologia. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349, 1857-1863.
34. Maschio, G.; Alberti, D.; Janin, G.; Locatelli, F.; Mann, J. F. E.; Motolose, M.; Ponticelli, C.; Ritz, E.; Zucchelli, P. and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 1996, 334, 939-945.
35. Jafar, T. H.; Schmid, C. H.; Landa, M.; Giatras, I.; Toto, R.; Remuzzi, G.; Maschio, G.; Brenner, B. M.; Kamper, A.; Zucchelli, P.; Becker, G.; Himmelmann, A.; Bannister, K.; Landais, P.; Shahinfar, S.; de Jong, P. E.; de Zeeuw, D.; Lau, J.; Levey, A. S. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001, 135, 73-87.
36. PROGRESS Collaborative Group, Randomized trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358, 1033-1041.
37. Dahlof, B.; Devereux, R.B.; Kjeldsen S. E.; Julius S.; Beevers G.; De Faire, U.; Fyhrquist, F.; Ibsen, H.; Kristiansson, K.; Lederballe-Pedersen, O.; Lindholm, L. H.; Nieminen, M. S.; Omvik P.; Oparil, S.; Wedel, H. The LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359(9311), 995-1003.
38. Mann, J.; Julius, S.; for the VALUE Trial Group. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998, 7, 176-183.
39. The ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349, 747-752.
40. Pitt, B.; Poole-Wilson, P. A.; Segal, R.; Martinez, F. A.; Dickstein, K.; Camm, A. J.; Konstam, M. A.; Riegger, G.; Klinger, G. H.; Neaton, J.; Sharma, D.; Thiyagarajan, B. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -the Losartan Heart Failure Survival Study, ELITE II. Lancet 2000, 355, 1582-1587.
41. Cohn, J. N.; Tognoni, G.; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (ValHeft trial). N. Engl. J. Med. 2001, 345, 1667-1675.
42. Brenner, B. M.; Cooper, M. E.; de Zeeuw, D.; Keane, W. F.; Mitch, W. E.; Parving, H. H.; Remuzzi, G.; Snapinn, S. M.; Zhang, Z.; Shahinfar, S.; for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345, 861-869.
43. Lewis, E. J.; Hunsicker, L. G.; Clarke, W. R.; Berl, T.; Pohl, M. A.; Lewis, J. B.; Ritz, E.; Atkins, R. C.; Rohde, R.; Raz, I.; for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345, 851-860.
44. Parving, H. H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345, 870-878.
45. Wheeldon, N. M.; Viberti, G.; for the MARVAL Trial. Microalbuminuria reduction with valsartan. (Abstract). Am. J. Hypertens. 2001, 14, 2A.
46. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J. Hypertens. 1999, 17, 151-183.
47. Feldman, R. D.; Campbell, N.; Larochelle, P.; Bolli, P.; Burgess, E. D.; Carruthers, S. G.; Floras, J. S.; Haynes, R. B.; Honos, G.; Leenen, F. H.; Leiter, L. A.; Logan, A. G.; Myers, M. G.; Spence, J. D.; Zarnke, K. B. 1999 Canadian recommendations for the management of hypertension. CMAJ 1999, 161 (suppl. 12), S1-S22.
48. Ramsay, L. E.; Williams, B.; Johnston, G. D.; MacGregor, G.; Poston, L.; Potter, J.; Poulter, N.; Russell, G. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J. Hum. Hypertens. 1999, 13, 569-592.
49. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on the detection, evaluation and treatment of high blood pressure (JNC VI). Arch. Intern. Med. 1997, 24, 2413-2446.
50. Baruch, L.; Anand, I.; Cohen, I. S.; Ziesche, S.; Judd, D.; Cohn, J. N. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure: Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999, 99, 2658-2664.
51. Moan, A.; Hoieggen, A.; Seljeflot, I.; Risanger, T.; Arnesen, H.; Kjeldsen, S. E. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J. Hypertens. 1996, 14, 1093-1097.
52. Stergiou, G. S.; Efstathiou, S. P.; Skeva, I. I.; Baibas, N. M.; Kalkana, C. B.; Mountokalakis, T. D. Assessment of drug effects on blood pressure and pulse pressure using measurements in the clinic, at home and with ambulatory monitoring. J. Hum. Hypertens. 2002, 16, 729-735.
53. Fossa, A. A.; DePasqual, M. J.; Ringer, L. J.; Winslow, R. L. Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin converting enzyme inhibitor with an angiotensin II receptor antagonist. Drug. Dev. Res. 1994, 33, 422-428.
54. Azizi, M.; Chatellier, G.; Guyene, T. T.; Murieta-Geoffroy, D.; Menard, J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995, 92, 825-834.
55. Azizi, M.; Guyene, T. T.; Chatellier, G.; Wargon, M.; Menard, J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997, 29, 634-640.
56. Richer, C.; Bruneval, P.; Menard, J.; Giudicelli, J. F. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 1998, 31, 692-698.
57. Webb, R. L.; Navarrete, A. E.; Davis, S.; de Gasparo, M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J. Hypertens. 1998, 16, 843-852.
58. Menard, J.; Campbell, D. J.; Azizi, M.; Gonzales, M. F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive rats. Circulation 1997, 96, 3072-3078
59. Stergiou, G. S.; Skeva, I. I.; Baibas, N. M.; Roussias, L.G.; Kalkana, C. B.; Achimastos, A. D.; Mountokalakis, T. D. Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension. J. Cardiovasc. Pharmacol. 2000, 35, 937-941.
60. Azizi, M.; Linhart, A.; Alexander, J.; Goldberg, A.; Menten, J.; Sweet, C.; Menard, J. Pilot study of combined blockade of the renin-angiotensin system in essential hypertension. J. Hypertens. 2000, 18, 1139-1147.
61. Mogensen, C. E.; Neldam, S.; Tikkanen, I.; Oren, S.; Viskoper, R.; Watts, R.; Cooper M. E. For the CALM Study Group. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. 2000, 321, 1440-1444.
62. Chrysant, S. G.; Fagan, T.; Glazer, R.; Kriegman, A. Effects of benazepril and hydrochlorothiazide given alone and in low- and high-dose combinations on blood pressure in patients with hypertension. Arch. Fam. Med. 1996, 5, 17-24.
63. Benz, J. R.; Black, H. R.; Craff, A.; Reed, A.; Fitzsimmons, S.; Shi, Y. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J. Hum. Hypertens. 1998, 12, 861-866.
64. Stergiou, G. S.; Malakos, J. S.; Achimastos, A. D.; Mountokalakis, T. D. Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring. J. Cardiovasc. Pharmacol. 1997, 29, 412-416.
65. Ruilope, L. M.; Aldigier, J. C.; Ponticelli, C.; Oddou-Stock, P.; Botteri, F.; Mann, J. F.; on behalf of the European group for the Investigation of valsartan in chronic renal disease. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J. Hypertens. 2000, 18, 89-95.
66. Hebert, L. A.; Falkenheim, M. E.; Nahman, N. S.; Cosio, F. G.; O'Dorisio, T. M. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am. J. Nephrol. 1999, 19, 1-6.
67. Russo, D.; Pisani, A.; Balletta, M. M.; de Nicola, L.; Savino, F. A.; Andreucci, M.; Minutolo, R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kid. Dis. 1999, 33, 851-856.
68. Yusuf, S.; From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis. Am. J. Cardiol. 2002, 89(suppl.), 18A-26A.
69. Sever, P. Intra-individual responses to blockade of the renin-angiotensin system by an ACE inhibitor (lisinopril) and an angiotensin receptor antagonist (candesartan). (Abstract). JRAAS 2000, 1, 104.
70. Stergiou, G. S.; Skeva, I. I.; Baibas, N. M.; Kalkana, C. B.; Roussias, L. G.; Mountokalakis, T. D. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism? Am. J. Hypertens. 2001, 14, 688-693.
71. Dickerson, J. E.; Hingorani, A. D.; Ashby, M. J.; Palmer, C. R.; Brown, M. J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353, 2008-2013.
72. Chalmers, J.; Wing, L.; Taylor, S. Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs. J. Hypertens. 1990, 8(suppl 4), S27-S35.
73. Attwood, S.; Bird, R.; Burch, K.; Casadei, B.; Coats, A.; Conway, J.; Dawes, M.; Ebbs, D.; Farmer, A.; Robinson, J. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J. Hypertens. 1994, 12, 1053-1060.
74. Niutta, E.; Cusi, D.; Colombo, R.; Pellizzoni, M.; Cesana, B.; Barlassina, C.; Soldati, L.; Bianchi, G. Predicting interindividual variations in antihypertensive therapy: the role of sodium transport systems and renin. J. Hypertens. 1990, 8(suppl. 4), S53-S58.
75. Bidiville, J.; Nussberger, J.; Waeber, G.; Porchet, M.; Waeber, B.; Brunner, H. R. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988, 11, 166-173.